1. Saicriti injectable acquisition - Board approved redeploying ₹83.83 cr into a 60% stake in Saicriti, adding \~15.47 crore units of EU-GMP/USFDA injectable capacity vs \~10.5 crore under the original upgrade, with completion targeted April 2027. This roughly doubles first-year throughput to \~₹110 cr and opens EU exports from FY29 - the company's first injectable-export accreditation.
2. Noumed vertical integration - Noumed shifts from distribution (\~10% margin) to manufacturing from FY27, with the Adelaide facility enabling local production and cutting inventory holding from 9-10 months to 5-6 months. This converts a 451-dossier Australian platform into higher-margin in-house supply, with 12 new product launches per year.
3. Prathyak R&D acquisition - ₹15 cr for 60% of Prathyak Laboratories, expected to complete by 30 September, brings a ready-made 150-SKU, 86-molecule pipeline with 65 personnel including 28 research scientists. This removes the 18-24 month timeline to assemble an R&D team and feeds the new injectable facility with transfer-ready products.
4. Philippines anti-TB contract - USD 11 million purchase order from Pill Corp, effective 1 June 2026, for exclusive supply of anti-TB products over 10 years. This follows 69 Philippines FDA dossier approvals and builds on the Philippines' 84% contribution to FY26 revenue.
5. Unit III expansion - Unit III scales from 24 crore to 45.1 crore units with ₹24.95 cr capex, completing October 2026. This absorbs Noumed's third-party volume and serves long-term export contracts, with utilization already at 87% in H1 FY26.
6. Dossier pipeline acceleration - 88 dossiers approved in FY26 plus 5 from Noumed, with 67 under development for commercialization in FY27-28. Australian-approved dossiers cut launch timelines from 18-24 months to 6-9 months, enabling rapid entry into LATAM, SE Asia, and Middle East.